Options
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Date Issued
2024-02-19
Author(s)
Sangro, B
Chan, S L
Kelley, R K
Lau, G
Kudo, M
Sukeepaisarnjaroen, W
Yarchoan, M
De Toni, E N
Furuse, J
Kang, Y K
Galle, P R
Rimassa, L
Heurgué, A
Tam, V C
Van Dao, T
Thungappa, S C
Breder, V
Ostapenko, Y
Reig, M
Makowsky, M
Paskow, M J
Gupta, C
Kurland, J F
Negro, A
Abou-Alfa, G K
Abstract
In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA.
Subjects
durvalumab; immune checkpoint inhibitor; overall survival; tremelimumab; unresectable hepatocellular carcinoma
Type
journal article